Literature DB >> 16545740

Continuing trials of GDNF in Parkinson's disease.

Roger A Barker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16545740     DOI： 10.1016/S1474-4422(06)70386-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  16 in total

1.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

3.  MANF improves the MPP+/MPTP-induced Parkinson's disease via improvement of mitochondrial function and inhibition of oxidative stress.

Authors:  Yigang Liu; Jingxing Zhang; Ming Jiang; Qiong Cai; Jianmin Fang; Lingjing Jin
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

4.  Manganese-Mediated Decrease in Levels of c-RET and Tyrosine Hydroxylase Expression In Vitro.

Authors:  Mayuko Y Kumasaka; Ichiro Yajima; Nobutaka Ohgami; Hiromasa Ninomiya; Machiko Iida; Xiang Li; Reina Oshino; Hiroko Tanihata; Masafumi Yoshinaga; Masashi Kato
Journal:  Neurotox Res       Date:  2017-07-20       Impact factor: 3.911

Review 5.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

6.  Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.

Authors:  Renan P Souza; Vincenzo de Luca; Gary Remington; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Albert H C Wong
Journal:  Psychopharmacology (Berl)       Date:  2010-04-06       Impact factor: 4.530

Review 7.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

8.  Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.

Authors:  John D Heiss; Codrin Lungu; Dima A Hammoud; Peter Herscovitch; Debra J Ehrlich; Davis P Argersinger; Sanhita Sinharay; Gretchen Scott; Tianxia Wu; Howard J Federoff; Kareem A Zaghloul; Mark Hallett; Russell R Lonser; Krystof S Bankiewicz
Journal:  Mov Disord       Date:  2019-05-30       Impact factor: 10.338

9.  GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Authors:  Catarina A R V Gomes; Patrícia F Simões; Paula M Canas; César Quiroz; Ana M Sebastião; Sergi Ferré; Rodrigo A Cunha; Joaquim A Ribeiro
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

10.  Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture.

Authors:  Fanny Schmidt; Pierre Champy; Blandine Séon-Méniel; Xavier Franck; Rita Raisman-Vozari; Bruno Figadère
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.